KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbbVie (ABBV) Total Liabilities (2016 - 2025)

AbbVie (ABBV) has disclosed Total Liabilities for 14 consecutive years, with $137.2 billion as the latest value for Q4 2025.

  • On a quarterly basis, Total Liabilities rose 4.09% to $137.2 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $137.2 billion, a 4.09% increase, with the full-year FY2025 number at $137.2 billion, up 4.09% from a year prior.
  • Total Liabilities was $137.2 billion for Q4 2025 at AbbVie, up from $136.5 billion in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $140.8 billion in Q1 2024 to a low of $121.2 billion in Q1 2023.
  • A 5-year average of $131.2 billion and a median of $133.3 billion in 2024 define the central range for Total Liabilities.
  • Peak YoY movement for Total Liabilities: skyrocketed 38.69% in 2021, then decreased 7.38% in 2022.
  • AbbVie's Total Liabilities stood at $131.1 billion in 2021, then decreased by 7.3% to $121.5 billion in 2022, then rose by 2.3% to $124.3 billion in 2023, then grew by 6.05% to $131.8 billion in 2024, then grew by 4.09% to $137.2 billion in 2025.
  • Per Business Quant, the three most recent readings for ABBV's Total Liabilities are $137.2 billion (Q4 2025), $136.5 billion (Q3 2025), and $137.4 billion (Q2 2025).